Boston Scientific Corporation (BSX) Shares Bought by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 0.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,189,297 shares of the medical equipment provider’s stock after purchasing an additional 4,651 shares during the quarter. Asset Management One Co. Ltd. owned about 0.16% of Boston Scientific worth $63,816,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Swiss National Bank raised its stake in Boston Scientific by 2.9% during the 2nd quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock valued at $154,814,000 after buying an additional 156,800 shares during the last quarter. Wells Fargo & Company MN increased its stake in Boston Scientific by 10.5% in the 2nd quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after buying an additional 867,983 shares in the last quarter. Sit Investment Associates Inc. increased its stake in Boston Scientific by 37.8% in the 3rd quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after buying an additional 38,855 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its stake in Boston Scientific by 35,016.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after buying an additional 3,033,800 shares in the last quarter. Finally, Greenwood Capital Associates LLC increased its stake in Boston Scientific by 71.7% in the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock worth $2,671,000 after buying an additional 38,249 shares in the last quarter. 90.57% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Corporation (NYSE:BSX) opened at $25.24 on Thursday. The stock has a market capitalization of $34,247.51, a PE ratio of 20.44, a P/E/G ratio of 1.92 and a beta of 0.96. Boston Scientific Corporation has a 1-year low of $20.36 and a 1-year high of $29.93. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.31. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. Boston Scientific’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.27 EPS. equities analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current year.

A number of equities research analysts have issued reports on the company. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. BMO Capital Markets reaffirmed a “buy” rating and issued a $31.00 price target on shares of Boston Scientific in a report on Wednesday, November 29th. BTIG Research raised shares of Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 price target for the company in a report on Thursday, November 30th. SunTrust Banks set a $33.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Monday. Finally, Cowen set a $31.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company. Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $30.97.

In related news, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $26.04, for a total transaction of $260,400.00. Following the sale, the executive vice president now owns 154,681 shares in the company, valued at approximately $4,027,893.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael P. Phalen sold 15,500 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $26.66, for a total value of $413,230.00. The disclosure for this sale can be found here. Insiders have sold a total of 424,698 shares of company stock valued at $12,273,553 in the last three months. 0.74% of the stock is owned by insiders.

WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/07/boston-scientific-corporation-bsx-shares-bought-by-asset-management-one-co-ltd.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit